17,810 results on '"COVID-19 complications"'
Search Results
2. Vaccination effects on reducing COVID‐19 complications in pregnancy: A large‐scale report from Iran.
- Author
-
Changizi, Nasrin, Eshrati, Babak, Salehi, Mohammadreza, Beheshtian, Maryam, Hadipour Jahromy, Leila, Emami Afshar, Nehzat, Hejazi, Saeideh, Hantoushzadeh, Sedigheh, Eslamian, Laleh, Savaie, Mohsen, Raeisi, Alireza, and Pooransari, Parichehr
- Subjects
- *
SARS-CoV-2 , *ARTIFICIAL respiration , *PREGNANCY complications , *COVID-19 , *VACCINATION - Abstract
Objective: The objective of this study was to evaluate the effects of maternal coronavirus disease 2019 (COVID‐19) vaccination on preventing severe complications of COVID‐19 in pregnant women. Methods: A retrospective study was conducted in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during pregnancy and/or for up to 6 weeks postpartum between September 1, 2021, to January 30, 2022. The data was retrieved from a national database. The pregnant women were divided into two groups of vaccinated and unvaccinated. The proposed outcomes (the need for hospitalization, intensive care unit admission, and mechanical ventilation and products of conception complications) were compared between the two groups. Results: Approximately 90 000 pregnant women infected with COVID‐19 were included in the study. The data of the vaccinated (19 922) and unvaccinated (70 147) groups were analyzed and compared. Pregnant patients in the vaccinated group had a significantly lower rate of hospitalization (21.2% vs 29.4%) (odds ratio [OR], 0.648 [95% confidence interval (CI), 0.625–0.673], P = 0.0001) and intensive care unit admission (3.7% vs 7.8%) (OR, 0.453 [95% CI, 0.382–0.535], P = 0.0001). The need for mechanical ventilation was also lower, although not statistically significant, in the vaccinated group than in the unvaccinated group (30 of 155 [19.4%] vs 418 of 1597 [26.2%]) (OR, 0.677 [95% CI, 0.448–1.024], P = 0.063). Cesarean section (54.3% vs 58.1%) (OR, 0.856 [95% CI, 0.751–0.977], P = 0.021) and stillbirth (0.4% vs 3.6%) (OR, 0.097 [95% CI, 0.026–0.252], P = 0.0001) were also significantly lower in the vaccinated patients. Most pregnant women in the vaccinated group (18 484–96.14%) received Sinopharm BIBP COVID‐19 inactivated vaccine. No significant differences were seen in the effect of different types of COVID‐19 vaccines on reducing COVID‐19 complications in infected pregnant patients. Conclusion: Maternal COVID‐19 immunization is effective in reducing COVID‐19 complications in infected pregnant women. Synopsis: Maternal coronavirus disease 2019 (COVID‐19) immunization is effective in reducing COVID‐19 complications in infected pregnant women. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting.
- Author
-
Briciu, Violeta, Leucuta, Daniel-Corneliu, Muntean, Monica, Radulescu, Amanda, Cismaru, Cristina, Topan, Adriana, Herbel, Lucia, Horvat, Melinda, Calin, Mihai, Dobrota, Roxana, and Lupse, Mihaela
- Subjects
SARS-CoV-2 ,SYMPTOMS ,COVID-19 ,VIRUS diseases ,COVID-19 pandemic ,ARACHNOID cysts - Abstract
The aim of this study was to evaluate differences in the clinical manifestations and outcomes in hospitalized patients with COVID-19 in a single Romanian center during four pandemic waves determined by different SARS-CoV-2 variants of concern (VOCs). A retrospective study on 9049 consecutive hospitalized adult patients was performed between 27 February 2020 and 31 March 2023. The study interval was divided into waves based on national data on SARS-CoV-2 VOCs' circulation. Multivariate logistic regression models were built, predicting death and complications as functions of comorbidities, therapy, wave, severity form, and vaccination status, and adjusted for ages ≥65 years. Pulmonary (pneumothorax/pneumomediastinum, pulmonary embolism) and extrapulmonary complications (liver injury, acute kidney injury, ischemic/hemorrhagic stroke, myocardial infarction, and gastrointestinal bleeding) were present, more frequently in ICU hospitalized patients and with differences between waves. The highest in-hospital mortality was found in patients presenting pneumothorax/pneumomediastinum. All of the evaluated risk factors were significantly associated with death, except for obesity and the Omicron wave. Our study highlights the changing nature of COVID-19 and acknowledges the impacts of viral mutations on disease outcomes. For all four waves, COVID-19 was a severe disease with a high risk of poor outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. COVID-19 and the need for special care for women with polycystic ovary syndrome: A systematic review [version 1; peer review: awaiting peer review]
- Author
-
Warda A. Alrubasy, Shams Khalid Sameer, Mohammad J. J. Taha, Mohammad T. Abuawwad, Abdalla Abu-Zeinh, Marwa Mahmood, Hebatullah Humeidan, Ahmad J. Taha, and Abdulqadir J. Nashwan
- Subjects
Systematic Review ,Articles ,Polycystic Ovary Syndrome (PCOS) ,COVID-19 complications ,Susceptibility to infection ,Chronic inflammatory state ,Renin-Angiotensin System (RAS) - Abstract
Objective The study investigates the association between coronavirus disease 2019 (COVID-19) and polycystic ovary syndrome (PCOS) and assess whether women with PCOS are at a higher susceptibility and risk for COVID-19 complications. Methods This review analyzes articles indexed in PubMed, Scopus, Google Scholar, and the Cochrane Library, focusing on the onset of the COVID-19 pandemic in December 1, 2019, until November 1, 2022. The quality of the evidence was assessed using the NIH quality assessment tool. The study was registered on PROSPERO (CRD42023371956) on January 12, 2023. Results A total of 11 observational studies were identified, totaling 22,155 PCOS patients. Despite the heterogeneity of the included studies, the findings of most of the studies were similar in terms of increased susceptibility and severity of COVID-19 infection in PCOS patients. PCOS patients were reported to have a 51% higher risk of COVID-19 infection than non-PCOS women (HR =1.51). Many causes have been identified to play a role, most notably the overactivation of the renin-angiotensin system (RAS) and elevated levels of RAS-associated proteins, decreased serum levels of neuropilin-1 (sNRP1), elevated serum biomarkers such as platelet degranulation and coagulation cascade markers increased acute phase response, and lower levels of vitamin D could render PCOS patients susceptible to a chronic inflammatory state, which can also lead to difficulties and severe consequences, when impacted by COVID-19. Furthermore, the COVID-19 pandemic also influenced psychological well-being, with an increase in the incidence and severity of depression and anxiety among PCOS patients in the COVID-19 pandemic era compared to healthy individuals. Conclusions Patients with PCOS are more likely to get infected with COVID-19 and display a higher affinity to severe infections and complications due to overlapping and confounding factors. These findings suggest that PCOS patients may need more medical attention when infected with COVID-19.
- Published
- 2024
- Full Text
- View/download PDF
5. The impact of excessive use of smart portable devices on neck pain and associated musculoskeletal symptoms. Prospective questionnaire-based study and review of literature
- Author
-
Kassem El Shunnar, Mahmoud Afeef Nisah, and Zeina H. Kalaji
- Subjects
Musculoskeletal disorder ,Shoulder Pain ,Neck Pain ,COVID-19 complications ,Surgery ,RD1-811 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Background: The rapid advancement of the digital revolution, normalization of portable smart gadgets, and internet-based communication have resulted in a perceptible shift and enhancement in human spine posture. They have also resulted however, in the emergence of health issues connected to the technique of usage. Neck pain, as well as other related symptoms, are the most commonly reported, as evidenced by the Coronavirus pandemic. People were urged to work from home when educational institutions and businesses were shut down. Students were given access to online learning facilities. Aim: The aim of this study is to demonstrate and clarify the increase in the number of young patients who suffer from neck pain and its associated symptoms; especially during the COVID 19 pandemic. The objective of this study is to investigate the impact of the excessive use of smart portable devices on neck pain and associated symptoms. This is most likely related to the incorrect posture of the neck, spine and body during utilization of these technologies. In addition, it aims to educate people about possible methods to prevent these medical morbidities. Methods: A cross-sectional study was conducted at Mediclinic City Hospital, Dubai Healthcare City, United Arab Emirates. Fifty-six patients were seen and evaluated as outpatients in the Neurosurgery clinic for neck pain. The Numerical Rating Pain Scale questionnaire (NMQ) was utilized to evaluate neck pain and other associated complaints such as back and musculoskeletal pain in general. The data was collected using a questionnaire with a 100% response rate from the patients. Cross tabulation and Chi Square analysis tool were designed to meet the study’s objective. Results: The findings show that smart phone and laptop use have significant effects on pain severity ranking among patients. For the factors “Time spent using smart phone/day” and Time spent using Laptop/day” were found to have a P value of 0.041 and 0.023; respectively. Conclusion: This research found a link between length of time spent using a mobile phone or laptop and the degree of neck discomfort.
- Published
- 2024
- Full Text
- View/download PDF
6. POST COVID EXTENSIVE VENOUS THROMBOSIS IN A PATIENT HAVING INFRAHEPATIC INTERRUPTION OF THE INFERIOR VENA CAVA (IVC) WITH AZYGOS CONTINUATION.
- Author
-
Faiz, Belqees Yawar, Mehboob, Amna, and Bhinder, Khurram Khaliq
- Subjects
- *
VENA cava inferior , *VENOUS thrombosis , *COVID-19 , *EMBRYOLOGY , *CONGENITAL disorders - Abstract
The failure of the hepatic and prerenal segments of the inferior vena cava (IVC) to merge during embryological development, leading to the persistence of either the azygous or hemiazygous vein, results in the rare condition "infrahepatic interruption of the IVC with azygos continuation" (0.6% prevalence). This anomaly is predisposed to IVC thrombosis due to restricted blood flow, resulting in venous hypertension, stasis, and thrombosis. Notably, hypercoagulability is a concern in COVID-19 patients. Here, we present a case of extensive post-COVID venous thrombosis in a 25-year-old male with infrahepatic interruption of the IVC and azygos continuation, following COVID-19 infection. The patient reported back pain and abdominal discomfort, with an MRI of the lumbar spine revealing extensive venous thrombosis in the IVC and iliofemoral veins, along with multiple venous collaterals. Subsequent contrast-enhanced CT imaging confirmed severe IVC stenosis or interruption, iliofemoral venous thrombosis, and azygous and hemiazygous connections. Radiologists must maintain a comprehensive understanding of the diverse congenital IVC anomalies to prevent diagnostic inaccuracies, and this knowledge proves equally crucial for surgeons and cardiologists in the context of preoperative planning. [ABSTRACT FROM AUTHOR]
- Published
- 2023
7. Jerne's "immune network theory", of interacting anti‐idiotypic antibodies applied to immune responses during COVID‐19 infection and after COVID‐19 vaccination.
- Author
-
Kurbel, Sven
- Subjects
- *
COVID-19 , *COVID-19 pandemic , *COVID-19 vaccines , *IMMUNE response , *IMMUNOGLOBULIN idiotypes , *IMMUNOGLOBULINS - Abstract
Niels Kaj Jerne has proposed the "immune network theory" of interactions among anti‐idiotypic antibodies, able to interfere with humoral responses to certain antigens. After the occurrence of the primary generation of antibodies, against an antigenic epitope, idiotypes of these antibodies induce anti‐idiotypic antibodies that modulate the intensity of the first response, and so on. Adverse effects following SARS‐COV‐2 COVID‐19 vaccines are occasionally similar to the symptoms of COVID‐19 infection. Rare events linked to SARS‐CoV‐2 vaccines also resemble some rarely reported COVID‐19 complications. Safety data from product information by European Medicines Agency suggest that spectra do overlap for four main vaccines. The proposition is that vaccine events and COVID‐19 complications are related to anti‐idiotypic antibodies whose spatial shape can lead to interactions with ACE2 molecules, in individuals with a prolonged Spike protein synthesis. The vaccines target cells by their affinity to the vaccine vector, or to engulf lipid nanoparticles. Anti‐idiotypic antibodies shaped similarly to the Spike protein possibly interact with ACE2 molecules and cause diverse signs and symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Brief review study on COVID-19 risks for complications in preterm birth and protective measures
- Author
-
Yee, Mon Mon, Soe, Ni Ni, Khine, Myat Soe, and Thidar, Aye Mya
- Published
- 2023
- Full Text
- View/download PDF
9. Secondary Headache Disorders Attributed to COVID-19 Complications
- Author
-
Genç, Hamit, Uludüz, Derya, Martelletti, Paolo, Series Editor, Özge, Aynur, editor, Uludüz, Derya, editor, Bolay, Hayrunnisa, editor, and Karadaş, Ömer, editor
- Published
- 2023
- Full Text
- View/download PDF
10. COVID-19 complications and economic recovery of China: guidelines for other economies
- Author
-
Soomro, Bahadur Ali, Mangi, Shah Nawaz, and Shah, Naimatullah
- Published
- 2023
- Full Text
- View/download PDF
11. The Association of Body Mass Index with COVID-19 Complications and Survival Rate at a Tertiary Hospital.
- Author
-
AlBahrani, Salma, Al-Maqati, Thekra N., Al Naam, Yaser A., Alqahtani, Jaber S., Alqahtani, Abdullah S., AlRabeeah, Saad, Aldhahir, Abdulelah M., Alkhalaf, Faisal, Alzuraiq, Hind R., Alenezi, Maryam Hamad, Alzahrani, Amal, Bakkar, Mohanad, Albahrani, Zainab, and Maawadh, Rawan M.
- Subjects
BODY mass index ,SURVIVAL rate ,COVID-19 pandemic ,RATINGS of hospitals ,COVID-19 ,POSITIVE pressure ventilation - Abstract
A high body mass index (BMI) is a known risk factor for coronavirus infection in hospitalized patients. Our study examined the association between BMI and complications and the survival rate among COVID-19 patients. This retrospective analysis used data from a tertiary hospital in the Eastern Region of Saudi Arabia during two waves of the COVID-19 pandemic. The study included 600 participants, with the majority being between 41 and 60 years old (41.3%) and men comprising 63.5% of the sample. Approximately 42.5% of patients were obese, and 31.3% were overweight. The results showed that BMI was significantly linked to respiratory diseases (p = 0.013); end-stage renal disease (p = 0.021); and cardiovascular disease (p = 0.003) but not diabetes mellitus (p = 0.064). Death occurred in 10.8% of patients; 33.8% were admitted to the ICU; 13.8% needed mechanical ventilation; and 60.7% had lung infiltration. Obese patients with oxygen saturation levels below 93% were 2.45 times more likely to require mechanical ventilation than those in the normal-weight group. Overweight and obese patients were also more likely to require mechanical ventilation than normal-weight patients, with odds ratios of 3.66 and 2.81, respectively. The BMI categorized was not associated with survival rate in COVID-19-hospitalized patients using Kaplan-Meier survival plots (p = 0.061). However, the BMI categorized was associated with survival rate in COVID-19 ICU patients (p < 0.001). In addition, the overweight showed a statistically significant higher hazard ratio of 2.22 (p = 0.01) compared to normal-weight patients using a Cox regression model. A high BMI was identified as an independent risk factor for reduced oxygen saturation (<93%), the need for mechanical ventilation, lung infiltration, mortality, and longer ICU stays in COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Wellens’ syndrome following severe COVID-19 infection, an innocent coincidence or a deadly association: two case reports
- Author
-
Georges Khattar, Jennifer Hallit, Carolla El Chamieh, and Elie Bou Sanayeh
- Subjects
COVID-19 ,Wellens’ syndrome ,Acute coronary syndrome ,Atherosclerosis ,COVID-19 complications ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Coronavirus disease 2019 (COVID-19) has been associated with late-onset cardiovascular complications primarily due to a hypercoagulable state. Its association with Wellens’ syndrome, which reflects a stenosis in the proximal left anterior descending coronary artery, is not well established. We present two cases diagnosed with this syndrome following their COVID-19 acute phase despite taking adequate anticoagulation. Case presentation We present two patients with incidental electrocardiography (ECG) showing the typical Wellens’-related changes, with an underlying severe triple-vessel coronary artery disease a few weeks following a severe COVID-19 infection associated with high inflammatory markers. The stenotic lesions were diagnosed by cardiac catheterization, and both patients underwent Coronary Artery Bypass Grafting successfully. Notably, patients’ baseline ECGs were normal, and they were maintained on Rivaroxaban 10 mg following their viral illness. Conclusion Despite advances in the preventive measures for COVID-19 complications, its pathophysiologic impact on vasculature and atherosclerosis is still incompletely understood. Further clinical trials must be conducted to study this association between Wellens’ syndrome and this virus to prevent life-threatening complications.
- Published
- 2023
- Full Text
- View/download PDF
13. Host genetic susceptibility underlying SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Brazilian Children
- Author
-
Cíntia Barros Santos-Rebouças, Rafael Mina Piergiorge, Cristina dos Santos Ferreira, Raquel de Seixas Zeitel, Alexandra Lehmkuhl Gerber, Marta Cristine Felix Rodrigues, Ana Paula de Campos Guimarães, Rodrigo Moulin Silva, Adriana Rodrigues Fonseca, Rangel Celso Souza, Ana Tereza Antunes Monteiro de Souza, Átila Duque Rossi, Luís Cristóvão de Moraes Sobrino Porto, Cynthia Chester Cardoso, and Ana Tereza Ribeiro de Vasconcelos
- Subjects
Multisystem Inflammatory Syndrome in Children ,SARS-CoV-2 ,COVID-19 complications ,Host genetics ,Admixed population ,Therapeutics. Pharmacology ,RM1-950 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Multisystem Inflammatory Syndrome in Children (MIS-C) is a life-threatening complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which manifests as a hyper inflammatory process with multiorgan involvement in predominantly healthy children in the weeks following mild or asymptomatic coronavirus disease 2019 (COVID-19). However, host monogenic predisposing factors to MIS-C remain elusive. Methods Herein, we used whole exome sequencing (WES) on 16 MIS-C Brazilian patients to identify single nucleotide/InDels variants as predisposition factors associated with MIS-C. Results We identified ten very rare variants in eight genes (FREM1, MPO, POLG, C6, C9, ABCA4, ABCC6, and BSCL2) as the most promising candidates to be related to a higher risk of MIS-C development. These variants may propitiate a less effective immune response to infection or trigger the inflammatory response or yet a delayed hyperimmune response to SARS-CoV-2. Protein–Protein Interactions (PPIs) among the products of the mutated genes revealed an integrated network, enriched for immune and inflammatory response mechanisms with some of the direct partners representing gene products previously associated with MIS-C and Kawasaki disease (KD). In addition, the PPIs direct partners are also enriched for COVID-19-related gene sets. HLA alleles prediction from WES data allowed the identification of at least one risk allele in 100% of the MIS-C patients. Conclusions This study is the first to explore host MIS-C-associated variants in a Latin American admixed population. Besides expanding the spectrum of MIS-C-associated variants, our findings highlight the relevance of using WES for characterising the genetic interindividual variability associated with COVID-19 complications and ratify the presence of overlapping/convergent mechanisms among MIS-C, KD and COVID-19, crucial for future therapeutic management.
- Published
- 2022
- Full Text
- View/download PDF
14. Prenatal and Neonatal Pulmonary Thrombosis as a Potential Complication of SARS-CoV-2 Infection in Late Pregnancy.
- Author
-
Abdulaziz-Opiela, Gazala, Sobieraj, Anna, Sibrecht, Greta, Bajdor, Julia, Mroziński, Bartłomiej, Kozłowska, Zuzanna, Iciek, Rafał, Wróblewska-Seniuk, Katarzyna, Wender-Ożegowska, Ewa, and Szczapa, Tomasz
- Subjects
- *
MULTISYSTEM inflammatory syndrome in children , *MULTISYSTEM inflammatory syndrome , *LOW-molecular-weight heparin , *SARS-CoV-2 , *THROMBOSIS , *MULLERIAN ducts - Abstract
Neonatal venous thrombosis is a rare condition that can be iatrogenic or occur due to viral infections or genetic mutations. Thromboembolic complications are also commonly observed as a result of SARS-CoV-2 infections. They can affect pediatric patients, especially the ones suffering from multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in neonates (MIS-N). The question remains whether the maternal SARS-CoV-2 infection during pregnancy can lead to thromboembolic complications in fetuses and neonates. We report on a patient born with an embolism in the arterial duct, left pulmonary artery, and pulmonary trunk, who presented several characteristic features of MIS-N, suspecting that the cause might have been the maternal SARS-CoV2 infection in late pregnancy. Multiple genetic and laboratory tests were performed. The neonate presented only with a positive result of IgG antibodies against SARS-CoV-2. He was treated with low molecular weight heparin. Subsequent echocardiographic tests showed that the embolism dissolved. More research is necessary to evaluate the possible neonatal complications of maternal SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Post‐COVID‐19‐associated multiorgan complications or "long COVID" with literature review and management strategy discussion: A meta‐analysis.
- Author
-
Iqbal, Phool, Ata, Fateen, Chaudhry, Hassan, Muthanna, Bassam, Waqas Younas, Hafiz, Munamm, Syed Ata ul, Sharma, Rohit, Fadah, Kahtan, Elazzazy, Shereen, Hamad, Anas, Said Abu Tabar, Osama, and Omar, Nabil E.
- Abstract
Objective: To investigate the post‐COVID‐19 long‐term complications or long COVID of various organ systems in patients after 3 months of the infection, specifically before the Omicron variant, with comparative literature analysis. Methods: A systemic literature search and meta‐analysis were conducted using multiple electronic databases (PubMed, Scopus, Cochrane library) with predefined search terms to identify eligible articles. Eligible studies reported long‐term complications of COVID‐19 infection before the Omicron variant infection. Case reports, case series, observational studies with cross‐sectional or prospective research design, case–control studies, and experimental studies that reported post‐COVID‐19 complications were included. The complications reported after 3 months after the recovery from COVID‐19 infection were included in the study. Results: The total number of studies available for analysis was 34. The effect size (ES) for neurological complications was 29% with 95% confidence interval (CI): 19%–39%. ES for psychiatric complications was 24% with 95% CI: 7%–41%. ES was 9% for cardiac outcomes, with a 95% CI of 1%–18%. ES was 22%, 95% CI: 5%–39% for the gastrointestinal outcome. ES for musculoskeletal symptoms was 18% with 95% CI: 9%–28%. ES for pulmonary complications was 28% with 95% CI: 18%–37%. ES for dermatological complications was 25%, with a 95% CI of 23%–26%. ES for endocrine outcomes was 8%, with a 95% CI of 8%–9%. ES size for renal outcomes was 3% with a 95% CI of 1%–7%. At the same time, other miscellaneous uncategorized outcomes had ES of 39% with 95% CI of 21%–57%. Apart from analyzing COVID‐19 systemic complications outcomes, the ES for hospitalization and intensive care unit admissions were found to be 4%, 95% CI: 0%–7%, and 11% with 95% CI: 8%–14%. Conclusion: By acquiring the data and statistically analyzing the post‐COVID‐19 complications during the prevalence of most virulent strains, this study has generated a different way of understanding COVID‐19 and its complications for better community health. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications
- Author
-
Yamamoto, Vicky, Bolanos, Joe F, Fiallos, John, Strand, Susanne E, Morris, Kevin, Shahrokhinia, Sanam, Cushing, Tim R, Hopp, Lawrence, Tiwari, Ambooj, Hariri, Robert, Sokolov, Rick, Wheeler, Christopher, Kaushik, Ajeet, Elsayegh, Ashraf, Eliashiv, Dawn, Hedrick, Rebecca, Jafari, Behrouz, Johnson, J Patrick, Khorsandi, Mehran, Gonzalez, Nestor, Balakhani, Guita, Lahiri, Shouri, Ghavidel, Kazem, Amaya, Marco, Kloor, Harry, Hussain, Namath, Huang, Edmund, Cormier, Jason, Ashford, J Wesson, Wang, Jeffrey C, Yaghobian, Shadi, Khorrami, Payman, Shamloo, Bahman, Moon, Charles, Shadi, Payam, and Kateb, Babak
- Subjects
Infectious Diseases ,Vaccine Related ,Prevention ,Aging ,Acquired Cognitive Impairment ,Emerging Infectious Diseases ,Brain Disorders ,Immunization ,Dementia ,Lung ,Mental Health ,Mental health ,Good Health and Well Being ,COVID-19 ,Coronavirus Infections ,Humans ,Immunotherapy ,Nutritional Support ,Pandemics ,Pneumonia ,Viral ,coronavirus ,COVID-19 diagnostics ,COVID-19 test ,mental health ,SARS-CoV-2 ,SARS-CoV-2 treatment ,Remdesivir ,Hydroxychloroquine ,Avigan ,Actemra ,COVID-19 Nutrition ,Rehabilitation ,COVID-19 Clinical manifestations ,COVID-19 Risk factors and comorbidities ,COVID-19 Vaccines ,COVID-19 immunotherapy ,COVID-19 Natural Killer Cells and stem cell therapy ,COVID-19 Janus Kinase Inhibitor 1 and 2 ,COVID-19 air filtration ,Nanomedicine for COVID-19 ,COVID-19 mental disorders ,COVID-19 domestic abuse ,Alzheimer's Disease and dementia ,COVID-19 complications ,COVID-19 Screening ,COVID-19 ophthalmology ,Neurological implications ,COVID-19 antiviral ,COVID-19 Steroids ,COVID-19 Convalescent plasma ,COVID-19 antico-agulants ,COVID-19 monoclonal antibodies ,COVID-19 Drug Treatment ,Alzheimer’s disease ,COVID-19 Neurological implications ,COVID-19 Alzheimer’s Disease and dementia ,COVID-19 Natural Killer Cells and stem cell therapy ,COVID-19 Rehabilitation ,COVID-19 anticoagulants ,COVID-19 monoclonal antibodies ,Clinical Sciences ,Neurosciences ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
COVID-19 is a severe infectious disease that has claimed >150,000 lives and infected millions in the United States thus far, especially the elderly population. Emerging evidence has shown the virus to cause hemorrhagic and immunologic responses, which impact all organs, including lungs, kidneys, and the brain, as well as extremities. SARS-CoV-2 also affects patients', families', and society's mental health at large. There is growing evidence of re-infection in some patients. The goal of this paper is to provide a comprehensive review of SARS-CoV-2-induced disease, its mechanism of infection, diagnostics, therapeutics, and treatment strategies, while also focusing on less attended aspects by previous studies, including nutritional support, psychological, and rehabilitation of the pandemic and its management. We performed a systematic review of >1,000 articles and included 425 references from online databases, including, PubMed, Google Scholar, and California Baptist University's library. COVID-19 patients go through acute respiratory distress syndrome, cytokine storm, acute hypercoagulable state, and autonomic dysfunction, which must be managed by a multidisciplinary team including nursing, nutrition, and rehabilitation. The elderly population and those who are suffering from Alzheimer's disease and dementia related illnesses seem to be at the higher risk. There are 28 vaccines under development, and new treatment strategies/protocols are being investigated. The future management for COVID-19 should include B-cell and T-cell immunotherapy in combination with emerging prophylaxis. The mental health and illness aspect of COVID-19 are among the most important side effects of this pandemic which requires a national plan for prevention, diagnosis and treatment.
- Published
- 2020
17. Wellens’ syndrome following severe COVID-19 infection, an innocent coincidence or a deadly association: two case reports
- Author
-
Khattar, Georges, Hallit, Jennifer, El Chamieh, Carolla, and Bou Sanayeh, Elie
- Published
- 2023
- Full Text
- View/download PDF
18. COVID-19 related vascular complications in a pediatric patient: A case report
- Author
-
Huda Al Hashemi, MBBS, Shaikh Saeed, MD, Ayoub Abedzadeh, MD, and Ahmed Al Hashmi, MBBS
- Subjects
Covid-19 ,vasculitis ,COVID-19 vasculitis ,COVID-19 complications ,Pediatric neuroradiology ,NEURORADIOLOGY ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
The novel coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus is a relatively recent infection that has resulted in a global pandemic, appearing first at the end of 2019. While initially presenting as a predominantly respiratory disease, with a classical picture of fever, dry cough, dyspnea and, in some cases anosmia and ageusia, recent cases have shown increasingly atypical and more systemic manifestation of the disease. A precise understanding of the extent and pathophysiology of COVID-19 remains underway to this day, particularly concerning its behavior in the pediatric population. Moreover, there has been an increasing number of COVID-19 reports with neurological complications and manifestations, prompting inquiry into neuroinvasion. Postulations include indirect invasion through a surge of inflammatory mediators “cytokine storm” and subsequent widespread endothelial injury; and direct neural tropism. We report the case of a previously healthy 12-year-old male presenting with acute right-sided hemiparesis, new-onset seizures and a generalized petechial rash. Laboratory tests revealed elevated inflammatory markers and radiological investigations confirmed an evolving left middle cerebral artery (MCA) infarct and large vessel vasculitis. Testing for SARS-CoV-2 infection was positive.
- Published
- 2022
- Full Text
- View/download PDF
19. Diagnostic Approaches to Acute Neuro-COVID
- Author
-
Cascella, Marco, De Blasio, Elvio, Cascella, Marco, and De Blasio, Elvio
- Published
- 2022
- Full Text
- View/download PDF
20. Post‐COVID‐19‐associated multiorgan complications or 'long COVID' with literature review and management strategy discussion: A meta‐analysis
- Author
-
Phool Iqbal, Fateen Ata, Hassan Chaudhry, Bassam Muthanna, Hafiz Waqas Younas, Syed Ata ul Munamm, Rohit Sharma, Kahtan Fadah, Shereen Elazzazy, Anas Hamad, Osama Said Abu Tabar, and Nabil E. Omar
- Subjects
COVID‐19 complications ,long COVID ,Meta‐analysis ,Post COVID‐19 ,SARS‐CoV‐2 sequelae ,Medicine - Abstract
Abstract Objective To investigate the post‐COVID‐19 long‐term complications or long COVID of various organ systems in patients after 3 months of the infection, specifically before the Omicron variant, with comparative literature analysis. Methods A systemic literature search and meta‐analysis were conducted using multiple electronic databases (PubMed, Scopus, Cochrane library) with predefined search terms to identify eligible articles. Eligible studies reported long‐term complications of COVID‐19 infection before the Omicron variant infection. Case reports, case series, observational studies with cross‐sectional or prospective research design, case–control studies, and experimental studies that reported post‐COVID‐19 complications were included. The complications reported after 3 months after the recovery from COVID‐19 infection were included in the study. Results The total number of studies available for analysis was 34. The effect size (ES) for neurological complications was 29% with 95% confidence interval (CI): 19%–39%. ES for psychiatric complications was 24% with 95% CI: 7%–41%. ES was 9% for cardiac outcomes, with a 95% CI of 1%–18%. ES was 22%, 95% CI: 5%–39% for the gastrointestinal outcome. ES for musculoskeletal symptoms was 18% with 95% CI: 9%–28%. ES for pulmonary complications was 28% with 95% CI: 18%–37%. ES for dermatological complications was 25%, with a 95% CI of 23%–26%. ES for endocrine outcomes was 8%, with a 95% CI of 8%–9%. ES size for renal outcomes was 3% with a 95% CI of 1%–7%. At the same time, other miscellaneous uncategorized outcomes had ES of 39% with 95% CI of 21%–57%. Apart from analyzing COVID‐19 systemic complications outcomes, the ES for hospitalization and intensive care unit admissions were found to be 4%, 95% CI: 0%–7%, and 11% with 95% CI: 8%–14%. Conclusion By acquiring the data and statistically analyzing the post‐COVID‐19 complications during the prevalence of most virulent strains, this study has generated a different way of understanding COVID‐19 and its complications for better community health.
- Published
- 2023
- Full Text
- View/download PDF
21. Host genetic susceptibility underlying SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Brazilian Children.
- Author
-
Santos-Rebouças, Cíntia Barros, Piergiorge, Rafael Mina, dos Santos Ferreira, Cristina, Seixas Zeitel, Raquel de, Gerber, Alexandra Lehmkuhl, Rodrigues, Marta Cristine Felix, Guimarães, Ana Paula de Campos, Silva, Rodrigo Moulin, Fonseca, Adriana Rodrigues, Souza, Rangel Celso, de Souza, Ana Tereza Antunes Monteiro, Rossi, Átila Duque, Porto, Luís Cristóvão de Moraes Sobrino, Cardoso, Cynthia Chester, and de Vasconcelos, Ana Tereza Ribeiro
- Abstract
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a life-threatening complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which manifests as a hyper inflammatory process with multiorgan involvement in predominantly healthy children in the weeks following mild or asymptomatic coronavirus disease 2019 (COVID-19). However, host monogenic predisposing factors to MIS-C remain elusive. Methods: Herein, we used whole exome sequencing (WES) on 16 MIS-C Brazilian patients to identify single nucleotide/InDels variants as predisposition factors associated with MIS-C. Results: We identified ten very rare variants in eight genes (FREM1, MPO, POLG, C6, C9, ABCA4, ABCC6, and BSCL2) as the most promising candidates to be related to a higher risk of MIS-C development. These variants may propitiate a less effective immune response to infection or trigger the inflammatory response or yet a delayed hyperimmune response to SARS-CoV-2. Protein–Protein Interactions (PPIs) among the products of the mutated genes revealed an integrated network, enriched for immune and inflammatory response mechanisms with some of the direct partners representing gene products previously associated with MIS-C and Kawasaki disease (KD). In addition, the PPIs direct partners are also enriched for COVID-19-related gene sets. HLA alleles prediction from WES data allowed the identification of at least one risk allele in 100% of the MIS-C patients. Conclusions: This study is the first to explore host MIS-C-associated variants in a Latin American admixed population. Besides expanding the spectrum of MIS-C-associated variants, our findings highlight the relevance of using WES for characterising the genetic interindividual variability associated with COVID-19 complications and ratify the presence of overlapping/convergent mechanisms among MIS-C, KD and COVID-19, crucial for future therapeutic management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. COVID-19-related Rhino-orbital-cerebral Mucormycosis.
- Author
-
Al-Ani, Raid M. and Al Tameemi, Khalid Mohsin
- Subjects
- *
MUCORMYCOSIS , *AMPHOTERICIN B , *OXYGEN therapy , *COVID-19 testing , *MEDICAL records , *NASAL surgery - Abstract
Background: There is an increasing number of COVID-19-related Rhino-orbital-cerebral mucormycosis (ROCM), especially from India. Objectives: To evaluate the demographic, clinical, radiological, and outcome of the COVID-19-related ROCM cases in a single center. Materials and Methods: The medical records of the patients with COVID-19-related ROCM were retrospectively reviewed. The study covered 22 months duration from March 2020 to December 2021 in Imam Hussain Medical City, Karbala city, Iraq. Results: Of the 14 patients with COVID-19-related ROCM, there were 71.4% males with a male-to-female ratio of 2.5:1. The median age was 61 years (age range: 27-80 years). There were 42.9% of patients with a history of being a current smoker. All patients had a history of DM, and 57.1% of patients had a history of hypertension. All patients were without a history of the previous episode of COVID-19 or taking the vaccine. The median duration from the COVID-19 diagnosis to the diagnosis of ROCM was 19 days (duration range of 10-40 days). Most of the cases were of severe type (57.1%). All of the patients were taking corticosteroid and oxygen therapy. Nasal obstruction, nasal discharge, cheek swelling, and necrotic tissue were clinical features in all patients. The majority of the cases were on the left side (71.4%). Stage 3 was found in 42.9%. Amphotericin B was used for all patients and surgical debridement in 13 cases. Five patients have died (35.7%). Conclusion: COVID-19-related ROCM is an aggressive disease associated with a high mortality rate of 35.7%. Early diagnosis and on-time initiation of treatment are recommended to get the best outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Population Risk Factors for Severe Disease and Mortality in COVID-19 in the United States during the Pre-Vaccine Era: A Retrospective Cohort Study of National Inpatient Sample.
- Author
-
Raj, Kavin, Yeruva, Karthik, Jyotheeswara Pillai, Keerthana, Kumar, Preetham, Agrawal, Ankit, Chandna, Sanya, Khuttan, Akhilesh, Tripathi, Shalini, Akella, Ramya, Gudi, Thulasi Ram, Watts, Abi, Toquica Gahona, Christian C, Bhagat, Umesh, Aedma, Surya Kiran, Jalal, Ayesha Tamkinat, Ganti, Shyam, Varadarajan, Padmini, and Pai, Ramdas G
- Subjects
DISEASE risk factors ,HEART failure ,COVID-19 ,ADULT respiratory distress syndrome ,COHORT analysis ,PRIMARY immunodeficiency diseases - Abstract
Background-Previous studies on coronavirus disease 2019 (COVID-19) were limited to specific geographical locations and small sample sizes. Therefore, we used the National Inpatient Sample (NIS) 2020 database to determine the risk factors for severe outcomes and mortality in COVID-19. Methods-We included adult patients with COVID-19. Univariate and multivariate logistic regression was performed to determine the predictors of severe outcomes and mortality in COVID-19. Results-1,608,980 (95% CI 1,570,803–1,647,156) hospitalizations with COVID-19 were included. Severe complications occurred in 78.3% of COVID-19 acute respiratory distress syndrome (ARDS) and 25% of COVID-19 pneumonia patients. The mortality rate for COVID-19 ARDS was 54% and for COVID-19 pneumonia was 16.6%. On multivariate analysis, age > 65 years, male sex, government insurance or no insurance, residence in low-income areas, non-white races, stroke, chronic kidney disease, heart failure, malnutrition, primary immunodeficiency, long-term steroid/immunomodulatory use, complicated diabetes mellitus, and liver disease were associated with COVID-19 related complications and mortality. Cardiac arrest, septic shock, and intubation had the highest odds of mortality. Conclusions-Socioeconomic disparities and medical comorbidities were significant determinants of mortality in the US in the pre-vaccine era. Therefore, aggressive vaccination of high-risk patients and healthcare policies to address socioeconomic disparities are necessary to reduce death rates in future pandemics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Predictors of Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection.
- Author
-
Mihai, Nicoleta, Lazar, Mihai, Tiliscan, Catalin, Barbu, Ecaterina Constanta, Chitu, Cristina Emilia, Stratan, Laurentiu, Ganea, Oana Alexandra, Arama, Sorin Stefan, Ion, Daniela Adriana, and Arama, Victoria
- Subjects
LIVER injuries ,HOSPITAL patients ,SARS-CoV-2 ,BLOOD cell count ,COVID-19 ,INTERSTITIAL lung diseases ,CHOLANGITIS - Abstract
Background and Objectives: SARS-CoV-2 infection is frequently associated with pneumonia but has a broad tissue tropism also leading to systemic complications (hematologic, gastro-intestinal, cardiac, neurologic, etc.). In this study, we aim to evaluate the impact of COVID-19 infection on the liver and to identify the risk factors/predictors for liver injury at admission to the hospital. Materials and Methods: We performed a retrospective cohort study on 249 patients, divided into two Group A (157 patients with liver involvement) and Group B (92 patients without liver involvement). We recorded demographic and lifestyle parameters, anthropometric parameters, comorbidities, clinical parameters, inflammation markers, complete blood count, coagulation, and biochemical parameters. Lung parenchyma, liver dimensions, and morphology were evaluated by computer tomography (CT) scans. Results: Patients with liver involvement had higher heart and respiratory rates, lower oxygen saturation (SO
2 ), and necessitated higher oxygen flow at admittance. We found higher serum levels of C-reactive protein, fibrinogen, ferritin, creatine kinase, lactate dehydrogenase (LDH), serum triglycerides, and lower values for serum albumin in Group A patients. The patients with liver involvement presented more extensive lung injury with higher percentages of alveolar, mixed, and interstitial lesions, an increase in liver dimensions, and lower density ranges for the liver parenchyma. The patients presented hepatocytolytic involvement in 26 cases (10.4% from the entire study population), cholestatic involvement in 63 cases (37.7% from the entire study population), and mixed liver involvement in 68 cases (37.7% from the entire study population). Conclusions: Liver involvement in COVID-19 patients is frequent, usually mild, and occurs mostly in male patients over 50 years old. Cholestatic and mixed liver injuries are more frequent than hepatocytolytic injuries. The severity of lung injury evaluated by CT scan, increased values of inflammatory markers, LDH, and low values of SO2 can be considered risk factors/predictors for liver injury at admission to the hospital. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia
- Author
-
Ismail A. Walbi, Hussain Alqhtani, Faleh Alqahtani, Saad Ahmed Alkahtani, Ali Mohamed Alshabi, Amer S. Alali, and Hassan A. Albarqi
- Subjects
Hydroxychloroquine ,COVID-19 incidence ,COVID-19 complications ,Rheumatoid arthritis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: The drug hydroxychloroquine (HCQ) is widely used to treat rheumatoid arthritis (RA) and has been repurposed for the treatment of COVID-19. This study aims to determine whether HCQ concentration levels in individuals with RA alter the incidence of COVID-19 or its complications. Methods: We collected plasma samples from 13 individuals with confirmed rheumatoid arthritis (RA) to measure HCQ concentration levels. The study included individuals at least 18 years old who had been taking HCQ for at least six months at daily doses ranging from 200 to 400 mg. Results: The study enrolled a total of 13 RA patients. All patients were chronic HCQ users. Among the 13 patients, 7 patients were receiving HCQ at a dose of 200 mg per day, and 6 patients were receiving HCQ at a dose of 400 mg per day. COVID-19 confirmed cases accounted for approximately 46% of all patients. Half of the infected patients (n = 3) were taking a daily dose of 200 mg daily, while the other half were taking 400 mg daily. COVID-19 symptoms ranged from mild to moderate, and the intensity of the symptoms was not severe enough to necessitate hospitalization. COVID-19 symptoms in RA patients included headache, fever, fatigue, dry cough, and loss of taste or smell. Conclusions: Our findings indicated that there was no correlation between HCQ concentrations in rheumatoid arthritis patients and the occurrence of COVID-19 or its complications.
- Published
- 2022
- Full Text
- View/download PDF
26. SARS-CoV-2 in a Southeastern US Hospital System: Interplay of Complications and Code Status Downgrades.
- Author
-
Schieffer, Sydney M., Pelland, Scott C., Hagopian, Colleen, and Cline, David M.
- Subjects
HOSPITALS ,STATISTICS ,COVID-19 ,CONFIDENCE intervals ,HUMAN comfort ,MULTIPLE regression analysis ,MULTIVARIATE analysis ,DO-not-resuscitate orders ,RETROSPECTIVE studies ,ACQUISITION of data ,PATIENTS ,FISHER exact test ,HOSPITAL mortality ,SEVERITY of illness index ,RISK assessment ,HOSPITAL care ,MEDICAL records ,EMERGENCY medical services ,CHI-squared test ,DESCRIPTIVE statistics ,DATA analysis software ,ODDS ratio ,PALLIATIVE treatment - Abstract
The article discusses the results of a study on the link between the mortality rate of COVID-19 and medical complications during hospital admissions of patients in the Southeastern U.S. Topics mentioned include the relation between code status downgrades, patient complications, and mortality, the impact of COVID-19 on palliative care and informed code status downgrades, and a discussion on life-sustaining interventions.
- Published
- 2022
- Full Text
- View/download PDF
27. Pulmonary Involvement in SARS-CoV-2 Infection Estimates Myocardial Injury Risk.
- Author
-
Dumea, Eduard, Lazar, Mihai, Barbu, Ecaterina Constanta, Chitu, Cristina Emilia, and Ion, Daniela Adriana
- Subjects
SARS-CoV-2 ,MYOCARDIAL injury ,CORONAVIRUS diseases ,DIASTOLIC blood pressure ,SYSTOLIC blood pressure ,TUMOR necrosis factors - Abstract
Background and Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection represents a pathology with primary pulmonary involvement and multisystemic impact, including cardiovascular injuries. The present study aimed to assess the value of clinical, biochemical, and imaging factors in COVID-19 patients in determining the severity of myocardial involvement, and to create a model that can be used toevaluate myocardial injury risk based on clinical, biochemical and imaging factors. Materials and Methods: We performed an observational cohort study on 150 consecutive patients, evaluating their age, sex, hospitalization period, peripheral oxygen saturation (SpO
2 ) in ambient air, systolic and diastolic blood pressure, heart rate, respiratory rate, biochemical markers of cardiac dysfunction (TnI, and NT-proBNP), inflammatory markers (C reactive protein (CRP), fibrinogen, serum ferritin, interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα)), D-dimers, lactate dehydrogenase (LDH), myoglobin and radio-imaging parameters. All patients underwent computerized tomography chest scan in the first two days following admission. Results: We observed elevated heart and respiratory rates, higher systolic blood pressure, and a lower diastolic blood pressure in the patients with cardiac injury; significant differences between groups were registered in TnI, NT-proBNP, LDH, CRP, and D-dimers. For the radiological parameters, we found proportional correlations with the myocardial injury for the severity of lung disease, number of pulmonary segments with alveolar consolidation, number of pulmonary lobes with pneumonia, crazy paving pattern, type of lung involvement, the extent of fibroatelectatic lesions and the mediastinal adenopathies. Conclusions: Myocardial injury occurred in 12% of patients in the study group. Ground glass opacities, interstitial interlobular septal thickening (crazy paving pattern), fibroatelectasic lesions and alveolar consolidations on CT scan were correlated with myocardial injury. Routine lung sectional imaging along with non-specific biomarkers (LDH, D-dimers, and CRP) can be further valuable in the characterization of the disease burden, thus impacting patient care. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Transient spontaneous osteonecrosis of the knee (SONK) shortly after SARS-CoV-2 infection: A report of 2 cases.
- Author
-
Malinowski, Konrad, Skowronek, Paweł, Hirschmann, Michael, Dong Woon Kim, Henry, Brandon Michael, Ebisz, Michał, Mostowy, Marcin, and Pękala, Przemysław A.
- Subjects
SARS-CoV-2 ,CORONAVIRUS diseases ,OSTEONECROSIS - Abstract
Background. This article describes 2 cases of post-coronavirus disease 2019 (COVID-19) transient spontaneous osteonecrosis of the knee (PCT-SONK) observed in patients who had previously recovered from COVID-19 without corticosteroid administration. Objectives. The possible pathomechanisms by which a recent SARS-CoV-2 infection may contribute as a causative factor for osteonecrosis are reviewed, and the differential diagnosis and treatment are discussed. Materials and methods. Two patients (males, 45- and 47-year-old) presented with sudden onset knee pain with no trauma history. The pain persisted during rest and at night. On magnetic resonance imaging (MRI), no subchondral bone thickening was observed; bone edema was diffusely distributed in the whole femoral condyle, in contrast to the more focal edema that is typically concentrated mainly around the subchondral region in classic SONK. Both patients were treated nonoperatively with no weight bearing and pharmacological agents, and complete resolution of symptoms was achieved. Results. A follow-up MRI 10 weeks after presentation revealed a near-complete loss of signal in the medial femoral condyle in both patients. Conclusions. Orthopedic surgeons should be cautious when sudden knee pain without concurrent trauma or a history of injury occurs shortly after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, even with mild COVID-19 illness. While some studies report the development of post-COVID-19 osteonecrosis after lower doses of corticosteroids and sooner after their administration than in comparable non-COVID-19 cases, our study is the first to report 2 cases with no corticosteroid administration at all. Therefore, the authors believe it adds to the body of knowledge on the potential connections between COVID-19 and PCT-SONK. The transient nature of symptoms and radiological findings suggest that aggressive surgical treatment of non-injury local bone edema occurring shortly after SARS-CoV-2 infection should be avoided. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. The Association of Body Mass Index with COVID-19 Complications and Survival Rate at a Tertiary Hospital
- Author
-
Salma AlBahrani, Thekra N. Al-Maqati, Yaser A. Al Naam, Jaber S. Alqahtani, Abdullah S. Alqahtani, Saad AlRabeeah, Abdulelah M. Aldhahir, Faisal Alkhalaf, Hind R. Alzuraiq, Maryam Hamad Alenezi, Amal Alzahrani, Mohanad Bakkar, Zainab Albahrani, and Rawan M. Maawadh
- Subjects
body mass index ,COVID-19 ,COVID-19 complications ,ICU ,Science - Abstract
A high body mass index (BMI) is a known risk factor for coronavirus infection in hospitalized patients. Our study examined the association between BMI and complications and the survival rate among COVID-19 patients. This retrospective analysis used data from a tertiary hospital in the Eastern Region of Saudi Arabia during two waves of the COVID-19 pandemic. The study included 600 participants, with the majority being between 41 and 60 years old (41.3%) and men comprising 63.5% of the sample. Approximately 42.5% of patients were obese, and 31.3% were overweight. The results showed that BMI was significantly linked to respiratory diseases (p = 0.013); end-stage renal disease (p = 0.021); and cardiovascular disease (p = 0.003) but not diabetes mellitus (p = 0.064). Death occurred in 10.8% of patients; 33.8% were admitted to the ICU; 13.8% needed mechanical ventilation; and 60.7% had lung infiltration. Obese patients with oxygen saturation levels below 93% were 2.45 times more likely to require mechanical ventilation than those in the normal-weight group. Overweight and obese patients were also more likely to require mechanical ventilation than normal-weight patients, with odds ratios of 3.66 and 2.81, respectively. The BMI categorized was not associated with survival rate in COVID-19-hospitalized patients using Kaplan-Meier survival plots (p = 0.061). However, the BMI categorized was associated with survival rate in COVID-19 ICU patients (p < 0.001). In addition, the overweight showed a statistically significant higher hazard ratio of 2.22 (p = 0.01) compared to normal-weight patients using a Cox regression model. A high BMI was identified as an independent risk factor for reduced oxygen saturation (
- Published
- 2023
- Full Text
- View/download PDF
30. The Potential Role of Vitamin B12 in the Prevention of COVID-19 Complications: A Narrative Review
- Author
-
Srinidhi Rai, Sindhu, Prajna, B. Shamantha Rai, and P. Rithesh Pakkala
- Subjects
vitamin b12 ,covid-19 complications ,acute respiratory distress syndrome ,mortality reduction ,immunomodulatory effect ,Microbiology ,QR1-502 - Abstract
The elderly are more prone to mortality from COVID-19 infection, as they are susceptible to develop acute respiratory distress syndrome (ARDS). For COVID-19 patients with ARDS caused by sepsis or septic shock, high-dose parenteral vitamin B12 appears to be a potential new treatment option. Vitamin B12 may play a substantial impact in COVID-19 morbidity and mortality reduction owing to its function in DNA synthesis, cellular control, improvement of anti-inflammatory immune responses, and decrease of pro-inflammatory responses. This review aims to assess the functional role of Vitamin B12 in COVID-19 in terms of its immunomodulatory effect, role in cellular and humoral immunity and maintaining the gut microbe homeostasis. From data inception to June 2021, accessible electronic databases were searched for research/review articles reporting on the function of Vitamin B12 in COVID-19. Scopus, Web of Science, PubMed, WHO worldwide research on COVID-19 and the clinical trials registration “https://clinicaltrials.gov/” were used to conduct the systematic search by using keywords: “COVID-19 and “Vitamin B12”. Also, based on these outcomes, it can be concluded that Vitamin B12 may have a potential role in preventing COVID-19 complications. Further, studies evaluating the role of Vitamin B12 in COVID-19 may open a new array of ideas on the optimal and the well-tolerated dose and timing of its administration in COVID-19 patients.
- Published
- 2021
- Full Text
- View/download PDF
31. Pulmonary embolism and gastric bleed with disseminated mucormycosis - treading dangerous waters
- Author
-
Nishant Kumar Chauhan, Ashish Agarwal, Naveen Dutt, Taruna Yadav, and Rishabh Kochar
- Subjects
acute pulmonary embolism ,COVID-19 complications ,gastrointestinal mucormycosis ,disseminated mucormycosis ,cerebral mucormycosis ,Medicine - Abstract
Mucormycosis is an opportunistic infection seen in immunocompromised patients or in surgical and trauma settings with Mucorales wound contamination. In immunocompetent people, disseminated mucormycosis is uncommon. To ensure survival, patients with mucormycosis require early diagnosis and aggressive treatment using a multi-modality approach. We present a case of disseminated mucormycosis in an immunocompetent patient who also had pulmonary embolism and gastrointestinal bleeding. A recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, identified retrospectively by a positive IgM against SARS-CoV-2, was the only risk factor present. This report emphasizes the increased risk of mucormycosis and thromboembolic complications following a recent SARS-CoV-2 infection, as well as its successful treatment with medical therapy alone.
- Published
- 2022
- Full Text
- View/download PDF
32. Post-COVID-19 complications in home and hospital-based care: A study from Dhaka city, Bangladesh
- Author
-
Salamat Khandker, Aivee Akther, Billal H. Syed, Rezoun Shafiullah, Kawsar Ahmed, Alauddin A. Chowdhury, and Salim Khan
- Subjects
COVID-19 complications ,Bangladesh ,hospital ,home treatment ,Other systems of medicine ,RZ201-999 ,Medical technology ,R855-855.5 - Abstract
A cross-sectional survey was undertaken to understand the management patterns and post-COVID-19 complications among hospital and home-treated participants. Retrospective information was collected from four COVID-19 dedicated hospitals and four selected community settings. Using probability proportional sampling, 925 participants were selected. Data were collected using a semi-structured questionnaire. Bivariate and multivariate logistic regression analysis and the exact chi-square tests were utilized to analyze the association between the studied variables. A total of 659 participants responded (response rate 70.93%); 375 from hospitals and 284 from communities. About 80% of participants were mild cases, 75% were treated at home, and 65% of hospital-treated participants were referred after home treatment. Participants treated at home-to hospital and directly in the hospital had 1.64 and 3.38 times longer recovery time respectively than what home-based participants had. A significant increasing trend (p
- Published
- 2022
- Full Text
- View/download PDF
33. Co-infection associated with SARS-CoV-2 and their management
- Author
-
Vivek P Chavda, Aayushi B Patel, Anjali Pandya, Lalitkumar K Vora, Vandana Patravale, Zara M Tambuwala, Alaa AA Aljabali, Ángel Serrano-Aroca, Vijay Mishra, and Murtaza M Tambuwala
- Subjects
antiphospholipid syndrome ,chronic pulmonary disease ,co-infections ,COVID-19 complications ,COVID-19 life cycle ,happy hypoxia ,Medicine ,Medicine (General) ,R5-920 - Abstract
SARS-CoV-2 was discovered in Wuhan, China and quickly spread throughout the world. This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills and hypoxia. Patients are still experiencing problems after recovering from COVID-19. This review covers COVID-19 and associated issues following recovery from COVID-19, as well as multiorgan damage risk factors and treatment techniques. Several unusual illnesses, including mucormycosis, white fungus infection, happy hypoxia and other systemic abnormalities, have been reported in recovered individuals. In children, multisystem inflammatory syndrome with COVID-19 (MIS-C) is identified. The reasons for this might include uncontrollable steroid usage, reduced immunity, uncontrollable diabetes mellitus and inadequate care following COVID-19 recovery.
- Published
- 2022
- Full Text
- View/download PDF
34. Pericardial Involvement in Severe COVID-19 Patients.
- Author
-
Lazar, Mihai, Barbu, Ecaterina Constanta, Chitu, Cristina Emilia, Anghel, Ana-Maria-Jennifer, Niculae, Cristian-Mihail, Manea, Eliza-Daniela, Damalan, Anca-Cristina, Bel, Adela-Abigaela, Patrascu, Raluca-Elena, Hristea, Adriana, and Ion, Daniela Adriana
- Subjects
PERICARDIAL effusion ,COVID-19 ,BLOOD cell count ,CONGESTIVE heart failure ,TYPE 2 diabetes - Abstract
Background and Objectives: SARS-CoV-2 has an extensive tissue tropism due to its ability to attach to the surfaces of cells through different receptors, leading to systemic complications. In this article, we aim to present the prevalence of pericardial effusions in patients with severe COVID-19, to identify the risk factors/predictors for pericardial involvement, and to evaluate its impact on overall mortality. Materials and Methods: We enrolled 100 patients with severe COVID-19 in our observational cohort study and divided them in two groups: Group A (27 patients with pericardial effusion) and Group B (73 patients without pericardial effusion). We recorded demographic and lifestyle parameters, anthropometric parameters, clinical parameters, inflammation markers, respiratory function parameters, complete blood count, coagulation parameters, and biochemical serum parameters. All patients were evaluated by computer tomography scans within 48 h of admission. Results: The median age was 61 years in both groups and the male/female ratio was 3.5 vs. 2.8 in Group A vs. Group B. We identified mild pericardial effusion (3–4 mm) in 62.9% patients and moderate pericardial effusion (5–9 mm) in 37.1% patients, with a median value of 4 [3;6] mm. The patients with pericardial effusion presented with higher percentages of obesity, type-2 diabetes mellitus, arterial hypertension, and congestive heart failure, without statistical significance. Increased values in cardiac enzymes (myoglobin, CK, CK-MB) and LDH were statistically associated with pericardial effusion. The overall mortality among the participants of the study was 24% (24 patients), 33.3% in Group A and 20.8% in Group B. Conclusions: Pericardial effusion has a high prevalence (27%) among patients with severe forms of COVID-19 and was associated with higher mortality. Pericardial effusion in our study was not associated with the presence of comorbidities or the extent of lung involvement. Overall mortality was 60% higher in patients with pericardial effusion. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins.
- Author
-
Nunez-Castilla, Janelle, Stebliankin, Vitalii, Baral, Prabin, Balbin, Christian A., Sobhan, Masrur, Cickovski, Trevor, Mondal, Ananda Mohan, Narasimhan, Giri, Chapagain, Prem, Mathee, Kalai, and Siltberg-Liberles, Jessica
- Subjects
- *
MOLECULAR mimicry , *SARS-CoV-2 , *VIRAL antigens , *AUTOIMMUNITY , *COVID-19 , *THROMBOPOIETIN receptors - Abstract
Molecular mimicry between viral antigens and host proteins can produce cross-reacting antibodies leading to autoimmunity. The coronavirus SARS-CoV-2 causes COVID-19, a disease curiously resulting in varied symptoms and outcomes, ranging from asymptomatic to fatal. Autoimmunity due to cross-reacting antibodies resulting from molecular mimicry between viral antigens and host proteins may provide an explanation. Thus, we computationally investigated molecular mimicry between SARS-CoV-2 Spike and known epitopes. We discovered molecular mimicry hotspots in Spike and highlight two examples with tentative high autoimmune potential and implications for understanding COVID-19 complications. We show that a TQLPP motif in Spike and thrombopoietin shares similar antibody binding properties. Antibodies cross-reacting with thrombopoietin may induce thrombocytopenia, a condition observed in COVID-19 patients. Another motif, ELDKY, is shared in multiple human proteins, such as PRKG1 involved in platelet activation and calcium regulation, and tropomyosin, which is linked to cardiac disease. Antibodies cross-reacting with PRKG1 and tropomyosin may cause known COVID-19 complications such as blood-clotting disorders and cardiac disease, respectively. Our findings illuminate COVID-19 pathogenesis and highlight the importance of considering autoimmune potential when developing therapeutic interventions to reduce adverse reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia.
- Author
-
Walbi, Ismail A., Alqhtani, Hussain, Alqahtani, Faleh, Alkahtani, Saad Ahmed, Mohamed Alshabi, Ali, Alali, Amer S., and Albarqi, Hassan A.
- Abstract
The drug hydroxychloroquine (HCQ) is widely used to treat rheumatoid arthritis (RA) and has been repurposed for the treatment of COVID-19. This study aims to determine whether HCQ concentration levels in individuals with RA alter the incidence of COVID-19 or its complications. We collected plasma samples from 13 individuals with confirmed rheumatoid arthritis (RA) to measure HCQ concentration levels. The study included individuals at least 18 years old who had been taking HCQ for at least six months at daily doses ranging from 200 to 400 mg. The study enrolled a total of 13 RA patients. All patients were chronic HCQ users. Among the 13 patients, 7 patients were receiving HCQ at a dose of 200 mg per day, and 6 patients were receiving HCQ at a dose of 400 mg per day. COVID-19 confirmed cases accounted for approximately 46% of all patients. Half of the infected patients (n = 3) were taking a daily dose of 200 mg daily, while the other half were taking 400 mg daily. COVID-19 symptoms ranged from mild to moderate, and the intensity of the symptoms was not severe enough to necessitate hospitalization. COVID-19 symptoms in RA patients included headache, fever, fatigue, dry cough, and loss of taste or smell. Our findings indicated that there was no correlation between HCQ concentrations in rheumatoid arthritis patients and the occurrence of COVID-19 or its complications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Prenatal and Neonatal Pulmonary Thrombosis as a Potential Complication of SARS-CoV-2 Infection in Late Pregnancy
- Author
-
Gazala Abdulaziz-Opiela, Anna Sobieraj, Greta Sibrecht, Julia Bajdor, Bartłomiej Mroziński, Zuzanna Kozłowska, Rafał Iciek, Katarzyna Wróblewska-Seniuk, Ewa Wender-Ożegowska, and Tomasz Szczapa
- Subjects
pulmonary thrombosis ,SARS-CoV-2 ,neonatal thrombosis ,COVID-19 complications ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Neonatal venous thrombosis is a rare condition that can be iatrogenic or occur due to viral infections or genetic mutations. Thromboembolic complications are also commonly observed as a result of SARS-CoV-2 infections. They can affect pediatric patients, especially the ones suffering from multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in neonates (MIS-N). The question remains whether the maternal SARS-CoV-2 infection during pregnancy can lead to thromboembolic complications in fetuses and neonates. We report on a patient born with an embolism in the arterial duct, left pulmonary artery, and pulmonary trunk, who presented several characteristic features of MIS-N, suspecting that the cause might have been the maternal SARS-CoV2 infection in late pregnancy. Multiple genetic and laboratory tests were performed. The neonate presented only with a positive result of IgG antibodies against SARS-CoV-2. He was treated with low molecular weight heparin. Subsequent echocardiographic tests showed that the embolism dissolved. More research is necessary to evaluate the possible neonatal complications of maternal SARS-CoV-2 infection.
- Published
- 2023
- Full Text
- View/download PDF
38. COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19 – Molecular Mechanisms and Research Perspectives
- Author
-
Cascella M, Del Gaudio A, Vittori A, Bimonte S, Del Prete P, Forte CA, Cuomo A, and De Blasio E
- Subjects
covid-19 ,sars-cov-2 ,covid-pain ,covid-19 complications ,Medicine (General) ,R5-920 - Abstract
Marco Cascella,1 Alfredo Del Gaudio,2 Alessandro Vittori,3 Sabrina Bimonte,1 Paola Del Prete,4 Cira Antonietta Forte,1 Arturo Cuomo,1 Elvio De Blasio2,5 1Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori-IRCCS-“Fondazione G. Pascale”, Naples, 80131, Italy; 2DSC Anestesia e Rianimazione 2, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, 71013, FG, Italy; 3Department of Anesthesiology and Critical Care, ARCO, Bambino Gesù Children’s Hospital, Rome, Italy; 4Direzione Scientifica, Istituto Nazionale Tumori-IRCCS-“Fondazione G. Pascale”, Naples, 80131, Italy; 5Multidisciplinary Emergency Unit for COVID-19 Campania, Naples, 80100, ItalyCorrespondence: Sabrina BimonteDivision of Anesthesia and Pain Medicine, Istituto Nazionale Tumori-IRCCS-“Fondazione G. Pascale”, Naples, 80131, ItalyTel +39 0815903221Email s.bimonte@istitutotumori.na.itAbstract: Although the respiratory manifestations of COVID-19 are predominant, signs and symptoms of an extra-pulmonary involvement are usually encompassed among the clinical picture of the disease. Several painful manifestations can occur during the acute phase but also as short- or long-term complications. Myalgia, joint pain, sore throat, abdominal pain, chest pain, and headache usually accompany respiratory symptoms, but they can also occur as isolated clinical findings or can be expressed regardless of the severity of COVID-19. On these premises, given the vast spectrum of clinical manifestations and the complexity of their pathogenesis, it would be more appropriate to refer to “COVID-pain”, an umbrella term useful for encompassing all these clinical manifestations in a separate chapter of the disease. In this scenario, we addressed the topic from a molecular perspective, trying to provide explanations for the underlying pathophysiological processes. Consequently, this narrative review is aimed at dissecting the mechanisms of acute and chronic painful manifestations, summarizing fundamental concepts on the matter, controversies, current research gaps, and potential developments in this field.Keywords: COVID-19, SARS-CoV-2, COVID-pain, COVID-19 complications
- Published
- 2021
39. Critical Care in Cardiac Surgery Patients with COVID-19: International and Own Experience
- Author
-
G. B. Koltunova, L. M. Avramenko, V. V. Voityuk, and K. P. Chyzh
- Subjects
cardiac surgery ,covid-19 complications ,hospital mortality ,perioperative management ,covid-19 critical care ,post-covid-19 respiratory failure ,pandemic ,acquired heart disease ,antimicrobial therapy ,corticosteroid therapy ,Surgery ,RD1-811 - Abstract
The widespread occurrence of coronavirus disease 2019 (COVID-19) in the world has led to a sharp de-crease in the number of cardiac surgery interventions and had a negative impact on treatment outcomes. We present an overview of the available literature on the effects of COVID-19 on cardiac surgery at this time. The lack of randomized studies and guidelines on the tactics of perioperative management of patients with cardiovascular pathology encourages to rely on isolated clinical cases presented in the literature. The presence of cardiovascular disease in COVID-19 patients has been identified as a risk factor associated with high morbidity and mortality from the first days of the pandemic. In addition to older age, chronic comorbidities increase the risk of severe COVID-19 infection as well as its lethal outcome. Among the predictors of 30-day mortality in COVID-19 patients in the postoperative period the following were under-lined: male sex (p˂0.001), high risk class according to the American Society of Anesthesiologists (ASA) (p˂0.001), age over 70 years (p˂0.001), emergency surgery (p = 0.026), oncological surgery (p = 0.046). To date, there are no studies on the perioperative management of cardiac surgery patients with acquired heart disease with persistent post-COVID-19 lung disease. We present the results of our own experience of perioperative management of a cardiac surgery patient with COVID-associated outpatient bilateral polysegmental pneumonia. Patients with cardiac surgery after COVID-19 required intensive preoperative preparation. Appointment of the proposed scheme of antibacterial therapy in combination with corticosteroids has reduced the intensity of inflammatory changes in lung tissue. Surgical improvement of intracardiac hemodynamics under cardiopulmonary bypass led to complete reduction of lung parenchyma injury and restoration of the respiratory system. Results. In patients with acquired heart disease, respiratory failure can be caused not only by post-COVID-19 lung injury, but also by impaired intracardiac hemodynamics with increased pulmonary artery pressure due to the initial heart disorders. Restoration of adequate gas exchange function in the group of post-COVID-19 patients is ineffective without timely cardiac surgery.
- Published
- 2021
- Full Text
- View/download PDF
40. Regional Anaesthesia in the Post-COVID Era.
- Author
-
Gürkan, Yavuz, Açıkalın, Eren Yavuz, Adanur, Umut Deniz, and Manici, Mete
- Subjects
- *
CUBITAL tunnel syndrome , *COVID-19 , *POSITIVE pressure ventilation , *VIRAL transmission , *ANESTHESIA , *PRESSURE ulcers - Abstract
COVID-19 pandemic has changed clinical practice significantly. Trying to avoid airway manipulation to reduce viral transmission favoured regional anaesthesia techniques over general anaesthesia when feasible. In this case report, we share the anaesthetic care of a 45-year-old male with a history of intensive care unit admission due to COVID, positive pressure ventilation, and ECMO support. The patient was diagnosed with cubital tunnel syndrome, and his treatment was successfully applied as surgical release under infraclavicular block. This case is discussed in relation to recent trends in anaesthesiology, regarding patients with COVID-19 history. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Impact of influenza vaccination history in the clinical course of older adults hospitalized with COVID-19.
- Author
-
Hernández-Hernández JG, Quintanilla-Flores DL, González-Galván CR, Nuzzolo-Shihadeh L, Camacho-Ortiz A, Salinas-Martínez R, and Morales-Delgado R
- Subjects
- Humans, Aged, Male, Female, Prospective Studies, Aged, 80 and over, Length of Stay statistics & numerical data, Vaccination, Respiration, Artificial statistics & numerical data, Intensive Care Units, COVID-19 prevention & control, COVID-19 complications, COVID-19 mortality, COVID-19 epidemiology, Influenza Vaccines, Hospitalization statistics & numerical data, Hospital Mortality, Influenza, Human prevention & control, Influenza, Human mortality, Influenza, Human epidemiology, Influenza, Human complications
- Abstract
Background and Purpose: Some studies have shown that influenza vaccination is associated with a lower risk of SARS-CoV-2 infection; in patients with COVID-19 infection, admission to intensive care is reduced, with less need for mechanical ventilation, shorter hospital stays, and reduced mortality. This study aimed to determine if a history of annual influenza vaccination impacts the clinical course of SARS-CoV-2 infection during hospitalization., Methods: This was an observational, prospective, cohort study of patients older than 65 admitted to the COVID-19 unit from January to June 2021. The history of influenza vaccination over the last 5 years was assessed in each patient during hospitalization. We measured the length of hospital stay, the need for admission to the intensive care unit (ICU), the patient's oxygen requirements, complications during hospitalization, and outcome (medical discharge or death). Patients with a history of vaccination against SARS-CoV-2 were not included., Results: We analyzed 125 patients, 50.4% (n=63) with history of influenza vaccination and 49.6% (n=62) without a history of influenza vaccination. In-hospital mortality was 44.8%, higher in the unvaccinated (54.8%) population (p=0.008). ICU admission was 27% higher in vaccinated (35%) patients (p=0.05). Patients without a history of influenza vaccination had a higher prevalence of cardiac (8% vs. 5%, p=0.04) and renal complications (29% vs. 13%, p=0.02). Patients with a history of vaccination had a greater need for invasive mechanical ventilation (25.4%, p=0.02)., Conclusion: In this study, a history of influenza vaccination in older adults with SARS-CoV-2 infection was related to lower in-hospital mortality., (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality.
- Author
-
Schofield J, Abrams ST, Jenkins R, Lane S, Wang G, and Toh CH
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Sepsis mortality, Sepsis blood, Prognosis, SARS-CoV-2 isolation & purification, Biomarkers, Protein Aggregates, Critical Illness, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation mortality, Disseminated Intravascular Coagulation etiology, Disseminated Intravascular Coagulation diagnosis, Amyloid metabolism, Fibrinogen analysis, Fibrinogen metabolism, COVID-19 blood, COVID-19 mortality, COVID-19 complications
- Abstract
Abstract: Microclots have been associated with various conditions, including postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. They have been postulated to be amyloid-fibrin(ogen) aggregates, but their role as a prognostic biomarker remains unclear. To examine their possible clinical utility, blood samples were collected for the first 96 hours from critically ill patients (n = 104) admitted to the intensive care unit (ICU). Detection was by staining platelet-poor plasma samples with thioflavin T and visualized by fluorescent microscopy. Image J software was trained to identify and quantify microclots, which were detected in 44 patients (42.3%) on ICU admission but not in the remaining 60 (57.7%) or the 20 healthy controls (0.0%). Microclots on admission to ICU were associated with a primary diagnosis of sepsis (microclots present in sepsis, 23/44 [52.3%] vs microclots absent in sepsis, 19/60 [31.7%]; P = .044). Multicolor immunofluorescence demonstrated that microclots consisted of amyloid-fibrinogen aggregates, which was supported by proteomic analysis. Patients with either a high number or larger-sized microclots had a higher likelihood of developing disseminated intravascular coagulation (odds ratio [OR], 51.4; 95% confidence interval [CI], 6.3-6721.1; P < .001) and had an increased probability of 28-day mortality (OR, 5.3; 95% CI, 2.0-15.6; P < .001). This study concludes that microclots, as defined by amyloid-fibrin(ogen) aggregates, are potentially useful in identifying sepsis and predicting adverse coagulopathic and clinical outcomes., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Association between maternal and perinatal outcomes and histological changes in the placenta of patients with Covid-19: A cohort study.
- Author
-
Rocha de Souza L, Ramos Amorim MM, Souza AS, Carvalho Pinto de Melo B, Tiné Cantilino C, de Oliveira Saunders MA, Jucá de Petribú M, Soares Lúcio L, Rodrigues Marinho J, de Oliveira Correia MEV, and Katz L
- Subjects
- Humans, Pregnancy, Female, Adult, Cohort Studies, Infant, Newborn, Placenta Diseases pathology, Placenta Diseases virology, Placenta Diseases epidemiology, COVID-19 pathology, COVID-19 complications, Placenta pathology, Placenta virology, Pregnancy Complications, Infectious virology, Pregnancy Complications, Infectious pathology, Pregnancy Complications, Infectious epidemiology, Pregnancy Outcome epidemiology, SARS-CoV-2
- Abstract
Although studies evaluated placental involvement in Covid-19 patients, few have assessed its association with clinical repercussions. The study aimed to determine the association between the clinical status and maternal and perinatal outcomes of patients with Covid-19 at delivery and changes in placental histology. It is so far the largest cohort evaluating placentas of patients infected by the SARS-CoV-2. A secondary analysis was conducted of a database from which a cohort of 226 patients, who tested real-time polymerase chain reaction-positive for Covid-19 at delivery and whose placentas were collected and submitted to pathology, was selected for inclusion. One or more types of histological changes were detected in 44.7% of the 226 placentas evaluated. The most common abnormalities were maternal vascular malperfusion (38%), evidence of inflammation/infection (9.3%), fetal vascular malperfusion (0.8%), fibrinoid changes and intervillous thrombi (0.4%). Oxygen use (P = .01) and need for admission to an intensive care unit (ICU) (P = .04) were less common in patients with placental findings, and hospital stay was shorter in these patients (P = .04). There were more fetal deaths among patients with evidence of inflammation/infection (P = .02). Fetal death, albeit uncommon, is associated with findings of inflammation/infection. Oxygen use and need for admission to an ICU were less common among patients with placental findings, probably due to the pregnancy being interrupted early. None of the other findings was associated with maternal clinical status or with adverse perinatal outcome., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
44. A case report of thrombocytopenic COVID-19 and Miller-Fisher syndrome on a concurrent chronic immune neuropathy.
- Author
-
Blackbourn L, Hamid U, Tokala J, and Blume G
- Subjects
- Humans, Male, Middle Aged, SARS-CoV-2, Thrombocytopenia, Miller Fisher Syndrome diagnosis, Miller Fisher Syndrome immunology, COVID-19 complications, COVID-19 immunology, Immunoglobulins, Intravenous therapeutic use
- Abstract
Rationale: Miller-Fisher syndrome (MFS) is a rare subtype of Guillain-Barre syndrome with classic features of ataxia, areflexia, and ophthalmoplegia that can be caused by a preceding infection including COVID-19. We present a current, asymptomatic thrombocytopenic COVID-19 infection as a cause of MFS in a 60-year-old male with a concurrent chronic immune neuropathy., Patient Concerns: A 60-year-old male presenting with acute symptoms of MFS including ataxia, areflexia, and ophthalmoplegia on a chronic immune neuropathy for at least 1 year and concurrent asymptomatic COVID-19 positive infection., Diagnosis: MFS suspected secondary to a current thrombocytopenic COVID-19 infection., Interventions: Five days of intravenous immune globulin with continued monthly intravenous immune globulin as an outpatient, follow-up long-term in a neuromuscular clinic, electromyography as an outpatient, and continued physical therapy., Outcomes: The patient significantly improved after initial treatment., Lessons: The full effect of COVID-19 on the various Guillain-Barre syndrome subtypes is unknown, although it clearly can be a cause of the various variants including being caused by a current, asymptomatic infection., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
45. The incidence of thrombosis with co-occurring thrombocytopenia prior to the SARS-CoV2 pandemic: A population-based study.
- Author
-
Liu Y, Goh CH, Shen D, Qiu H, Huang KC, Luo M, Chen Z, and Tang CH
- Subjects
- Humans, Female, Male, Middle Aged, Incidence, Aged, Retrospective Studies, Taiwan epidemiology, Adult, SARS-CoV-2 isolation & purification, Young Adult, Aged, 80 and over, Databases, Factual, Adolescent, Pandemics, COVID-19 complications, COVID-19 epidemiology, Thrombocytopenia epidemiology, Thrombocytopenia complications, Thrombosis epidemiology, Thrombosis etiology, Thrombosis complications
- Abstract
Background: Thrombosis with thrombocytopenia syndrome (TTS) is a very rare prothrombotic disorder that is a safety concern for some COVID-19 vaccines. We aimed to devise a case definition to estimate the incidence of thrombosis with thrombocytopenia as a proxy for TTS in a national insurance claims database., Methods: We conducted a retrospective observational study using the National Health Insurance Research Database (NHIRD) in Taiwan over the three-year period prior to the SARS-COV-2 pandemic (2017-2019). Our case definition was all patients with newly diagnosed thrombosis co-occurring with a diagnosis of thrombocytopenia within seven days before or after the thrombosis diagnosis. Cases were identified using International Classification of Disease-10 codes., Findings: We identified 2010 patients with newly diagnosed thrombosis co-occurring with thrombocytopenia during the study period. The mean age was 64.71 years; female:male ratio 1:1.45. The most frequent thrombotic events were coronary artery disease (18.81%), cerebral infarction (16.87%), and disseminated intravascular coagulation (13.13%). Cerebral venous sinus thrombosis was rare (<0.1%). The average annual incidence rate of co-occurring new diagnoses of thrombosis and thrombocytopenia was 2.84 per 100 000 population. Incidence rates were higher in men than women, except in 20-39 year-olds (higher in females). 20.6% of patients died within the first month after diagnosis., Interpretation: We observed that the demographic and clinical characteristics of thrombosis with co-occurring thrombocytopenia using our case definition is different from that of TTS. Further research is needed to refine the case definition of TTS in the post-COVID-19 vaccination period., Competing Interests: The authors have read the journal’s policy and have the following competing interests: CHG, KCH, and HQ are employees of Johnson & Johnson, Office of the Chief Medical Officer. ML and ZC are employees of Janssen China Research & Development. YL is an employee of Janssen Pharmaceuticals LLC, United States. HQ, YL, ML and ZC hold stock in Johnson & Johnson. CHT and DS declare no conflicts of interest. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
46. Risks of incident major osteoporotic fractures following SARS-CoV-2 infection among older individuals: a population-based cohort study in Hong Kong.
- Author
-
Lui DTW, Xiong X, Cheung CL, Lai FTT, Li X, Wan EYF, Chui CSL, Chan EWY, Cheng FWT, Chung MSH, Au ICH, Lee CH, Ip TP, Woo YC, Tan KCB, Wong CKH, and Wong ICK
- Subjects
- Humans, Hong Kong epidemiology, Female, Male, Aged, Middle Aged, Retrospective Studies, Risk Factors, Incidence, Aged, 80 and over, Proportional Hazards Models, Cohort Studies, COVID-19 epidemiology, COVID-19 complications, SARS-CoV-2, Osteoporotic Fractures epidemiology
- Abstract
Population-based epidemiological studies on post-acute phase coronavirus 2019 (COVID-19)-related fractures in older adults are lacking. This study aims to examine the risk of incident major osteoporotic fractures following SARS-CoV-2 infection among individuals aged ≥50, compared to individuals without COVID-19. It was a retrospective, propensity-score matched, population-based cohort study of COVID-19 patients and non-COVID individuals identified from the electronic database of the Hong Kong Hospital Authority from January 2020 to March 2022. The primary outcome was a composite of major osteoporotic fractures (hip, clinical vertebral, and upper limb). COVID-19 patients were 1:1 matched to controls using propensity-score according to age, sex, vaccination status, medical comorbidities and baseline medications. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. A total of 429 459 COVID-19 patients were included, 1:1 matched to non-COVID individuals. Upon median follow-up of 11 months, COVID-19 patients had higher risks of major osteoporotic fractures (5.08 vs 3.95 per 1000 persons; HR 1.22 95%CI [1.15-1.31]), hip fractures (2.71 vs 1.94; 1.33 [1.22-1.46]), clinical vertebral fractures (0.42 vs 0.31; 1.29 [1.03-1.62]), and falls (13.83 vs 10.36; 1.28 [1.23-1.33]). Subgroup analyses revealed no significant interaction. In acute (within 30 days) and post-acute phases (beyond 30 days) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we consistently observed a significant increase in fractures and falls risks. Our study demonstrated increased risk of major osteoporotic fractures after SARS-CoV-2 infection in both acute and post-acute phases in older adults, partly due to increased fall risk. Clinicians should be aware of musculoskeletal health of COVID-19 survivors., (© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
47. Long-COVID autonomic syndrome in working age and work ability impairment.
- Author
-
Rinaldi L, Rigo S, Pani M, Bisoglio A, Khalaf K, Minonzio M, Shiffer D, Romeo MA, Verzeletti P, Ciccarelli M, Bordoni MG, Stranges S, Riboli E, Furlan R, and Barbic F
- Subjects
- Humans, Male, Middle Aged, Female, Prospective Studies, Italy epidemiology, Adult, SARS-CoV-2 isolation & purification, Autonomic Nervous System Diseases physiopathology, Autonomic Nervous System Diseases epidemiology, Post-Acute COVID-19 Syndrome, Return to Work, Autonomic Nervous System physiopathology, Surveys and Questionnaires, COVID-19 complications, COVID-19 physiopathology, COVID-19 epidemiology, COVID-19 virology
- Abstract
Long-COVID19 has been recently associated with long-sick leave and unemployment. The autonomic nervous system functioning may be also affected by SARS-CoV-2, leading to a chronic autonomic syndrome. This latter remains widely unrecognized in clinical practice. In the present study, we assessed the occurrence of Long-COVID19 Autonomic Syndrome in a group of active workers as well as the relationships between their autonomic dysfunction and work ability. This prospective observational study was conducted during the 2nd wave of the pandemic in Italy. Forty-five patients (53.6 ± 8.4 years; 32 M) hospitalized for COVID19, were consecutively enrolled at the time of their hospital discharge (T0) and followed-up for 6 months. Autonomic symptoms and work ability were assessed by COMPASS31 and Work Ability Index questionnaires at T0, one (T1), three and six (T6) months after hospital discharge and compared to those retrospectively collected for a period preceding SARS-CoV-2 infection. Clinical examination and standing test were also performed at T1 and T6. One in three working-age people developed a new autonomic syndrome that was still evident 6 months after the acute infection resolution. This was associated with a significant reduction in the work ability. Recognition of Long-COVID19 Autonomic Syndrome may promote early intervention to facilitate return to work and prevent unemployment., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
48. COVID-19 was associated with the complications after allogeneic hematopoietic stem cell transplantation.
- Author
-
Wen Q, Guo Z, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Sun YQ, Huang XJ, and Mo XD
- Subjects
- Humans, Male, Female, Middle Aged, Adult, SARS-CoV-2 isolation & purification, Severity of Illness Index, Aged, Cytomegalovirus Infections complications, Retrospective Studies, Young Adult, COVID-19 complications, COVID-19 mortality, Hematopoietic Stem Cell Transplantation adverse effects, Transplantation, Homologous adverse effects
- Abstract
We aimed to identify the severity and duration of COVID-19 infection on complications after allo-HSCT. Enrolled 179 hospitalized patients with COVID-19 were categorized into long-term infection (> 18 days, n = 90) or short-term infection group (≤ 18 days, n = 89) according to the median duration of COVID-19. The severity of COVID-19 was categorized as asymptomatic infection, mild, moderate, severe, and critical illness according to guidelines of National Institutes of Health. Particularly, severe illness and critical illness were classified as serious infection. Asymptomatic infection, mild illness and moderate illness were classified as non-serious infection. The 150-day probabilities of poor graft function (PGF), cytomegalovirus (CMV) pneumonia and non-relapse mortality (NRM) were significantly higher in long-term infection group. The 150-day probabilities of CMV pneumonia and NRM after COVID-19 were higher in serious infection group. The 150-day probabilities of overall survival (OS) was significantly lower in long-term and serious infection group. In multivariable analysis, the severity of COVID-19 was associated with NRM and OS, and the duration of COVID-19 was associated with PGF. In summary, our data reported that the severity and duration of COVID-19 were associated with several complications and contribute to poor outcomes after allo-HSCT., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
49. Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19.
- Author
-
Alkhateeb T, Stollings JL, Sohn I, Liu D, Fleenor LM, Ely EW, and Lahiri S
- Subjects
- Humans, Male, Female, Middle Aged, Aged, COVID-19 Drug Treatment, Intensive Care Units, SARS-CoV-2 isolation & purification, Interleukin-6, Antibodies, Monoclonal, Humanized therapeutic use, Delirium drug therapy, COVID-19 complications, COVID-19 mortality, Coma etiology, Coma drug therapy, Critical Illness
- Abstract
Recent preclinical studies demonstrate a direct pathological role for the interleukin-6 (IL-6) pathway in mediating structural and functional delirium-like phenotypes in animal models of acute lung injury. Tocilizumab, an IL-6 pathway inhibitor, has shown reduced duration of ventilator dependency and mortality in critically ill patients with COVID-19. In this study, we test the hypothesis that tocilizumab is associated with reduced delirium/coma prevalence in critically ill patients with COVID-19. 253 patients were included in the study cohort, 69 in the tocilizumab group and 184 in the historical control group who did not receive tocilizumab. Delirium was assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) with a positive score indicating delirium. Coma was defined as a Richmond Agitation-Sedation Scale score of - 4 or - 5. Tocilizumab was associated with significantly greater number of days alive without delirium/coma (tocilizumab [7 days (IQR: 3-9 days)] vs control [3 days (IQR: 1-8 days)]; p < 0.001). These results remained significant after adjusting for age, sex, sepsis, Charlson Comorbidity Index, Sequential Organ Failure Assessment score, and median daily dose of analgesics/sedatives ( β ^ = 0.671, p = 0.010). There were no significant differences in mortality ( β ^ = - 0.204, p = 0.561), ventilator duration ( β ^ = 0.016, p = 0.956), and ICU or hospital length of stay ( β ^ = - 0.134, p = 0.603; β ^ = 0.003, p = 0.991, respectively). Tocilizumab use was associated with significantly increased number of days without delirium/coma. Confirmation of these findings in randomized prospective studies may inform a novel paradigm of pharmacological amelioration of delirium/coma during critical illness., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
50. Acute subglottic laryngitis: an uncommon SARS-CoV-2 complication.
- Author
-
Mathieson T and Leuchter I
- Subjects
- Humans, Male, Acute Disease, Female, Middle Aged, COVID-19 complications, Laryngitis virology, Laryngitis etiology, Laryngitis diagnosis, SARS-CoV-2
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.